Matches in SemOpenAlex for { <https://semopenalex.org/work/W2312279372> ?p ?o ?g. }
- W2312279372 endingPage "1090" @default.
- W2312279372 startingPage "1079" @default.
- W2312279372 abstract "BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.ObjectiveWe sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis.MethodsTwelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. Biopsy specimens were examined for psoriatic epidermal features (thickness, Ki67+ keratinocytes and keratin 16 [KRT16] mRNA expression, and phosphorylated signal transducer and activator of transcription [pSTAT]+ nuclei) and T-cell and dendritic cell (DC) subsets by using immunohistochemistry, and mRNA transcripts were quantified by using a microarray.ResultsIn lesional skin keratinocyte pSTAT1 and pSTAT3 staining was increased at baseline but reduced after 1 day of tofacitinib (baseline, median of 1290 pSTAT1+ cells/μm2; day 1, median of 332 pSTAT1+ cells/μm2; and nonlesional, median of 155 pSTAT1+ cells/μm2). Epidermal thickness and KRT16 mRNA expression were significantly and progressively reduced after days 1 and 3 of tofacitinib administration, respectively (eg, KRT16 decreased 2.74-fold, day 3 vs baseline, P = .016). Decreases in DC and T-cell numbers were observed after weeks 1 and 2, respectively. At week 4, significant decreases in IL-23/TH17 pathways were observed that persisted through week 12. Improvements in clinical and histologic features were strongly associated with changes in expression of psoriasis-related genes and reduction in IL-17 gene expression.ConclusionsTofacitinib has a multitiered response in patients with psoriasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte-induced cytokine signaling, leading to reductions in pathologic DC and T-cell numbers to nonlesional levels; and (3) inhibition of the IL-23/TH17 pathway. Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. Biopsy specimens were examined for psoriatic epidermal features (thickness, Ki67+ keratinocytes and keratin 16 [KRT16] mRNA expression, and phosphorylated signal transducer and activator of transcription [pSTAT]+ nuclei) and T-cell and dendritic cell (DC) subsets by using immunohistochemistry, and mRNA transcripts were quantified by using a microarray. In lesional skin keratinocyte pSTAT1 and pSTAT3 staining was increased at baseline but reduced after 1 day of tofacitinib (baseline, median of 1290 pSTAT1+ cells/μm2; day 1, median of 332 pSTAT1+ cells/μm2; and nonlesional, median of 155 pSTAT1+ cells/μm2). Epidermal thickness and KRT16 mRNA expression were significantly and progressively reduced after days 1 and 3 of tofacitinib administration, respectively (eg, KRT16 decreased 2.74-fold, day 3 vs baseline, P = .016). Decreases in DC and T-cell numbers were observed after weeks 1 and 2, respectively. At week 4, significant decreases in IL-23/TH17 pathways were observed that persisted through week 12. Improvements in clinical and histologic features were strongly associated with changes in expression of psoriasis-related genes and reduction in IL-17 gene expression. Tofacitinib has a multitiered response in patients with psoriasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte-induced cytokine signaling, leading to reductions in pathologic DC and T-cell numbers to nonlesional levels; and (3) inhibition of the IL-23/TH17 pathway." @default.
- W2312279372 created "2016-06-24" @default.
- W2312279372 creator A5009213880 @default.
- W2312279372 creator A5030830562 @default.
- W2312279372 creator A5037177516 @default.
- W2312279372 creator A5037386752 @default.
- W2312279372 creator A5038023238 @default.
- W2312279372 creator A5044627353 @default.
- W2312279372 creator A5059435575 @default.
- W2312279372 creator A5074081568 @default.
- W2312279372 creator A5076696600 @default.
- W2312279372 creator A5076795570 @default.
- W2312279372 creator A5080337749 @default.
- W2312279372 creator A5087213651 @default.
- W2312279372 creator A5089890051 @default.
- W2312279372 creator A5089961811 @default.
- W2312279372 creator A5090674996 @default.
- W2312279372 date "2016-04-01" @default.
- W2312279372 modified "2023-10-17" @default.
- W2312279372 title "Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study" @default.
- W2312279372 cites W1586082586 @default.
- W2312279372 cites W1907172463 @default.
- W2312279372 cites W1981177225 @default.
- W2312279372 cites W1991658642 @default.
- W2312279372 cites W2018107887 @default.
- W2312279372 cites W2028648418 @default.
- W2312279372 cites W2039941902 @default.
- W2312279372 cites W2042118950 @default.
- W2312279372 cites W2079598877 @default.
- W2312279372 cites W2087178163 @default.
- W2312279372 cites W2096877370 @default.
- W2312279372 cites W2103018315 @default.
- W2312279372 cites W2121219094 @default.
- W2312279372 cites W2138647255 @default.
- W2312279372 cites W2145544715 @default.
- W2312279372 cites W2145834141 @default.
- W2312279372 cites W2146247267 @default.
- W2312279372 cites W2149189075 @default.
- W2312279372 cites W2162548536 @default.
- W2312279372 cites W4233561050 @default.
- W2312279372 cites W4237627879 @default.
- W2312279372 doi "https://doi.org/10.1016/j.jaci.2015.12.1318" @default.
- W2312279372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27059729" @default.
- W2312279372 hasPublicationYear "2016" @default.
- W2312279372 type Work @default.
- W2312279372 sameAs 2312279372 @default.
- W2312279372 citedByCount "109" @default.
- W2312279372 countsByYear W23122793722016 @default.
- W2312279372 countsByYear W23122793722017 @default.
- W2312279372 countsByYear W23122793722018 @default.
- W2312279372 countsByYear W23122793722019 @default.
- W2312279372 countsByYear W23122793722020 @default.
- W2312279372 countsByYear W23122793722021 @default.
- W2312279372 countsByYear W23122793722022 @default.
- W2312279372 countsByYear W23122793722023 @default.
- W2312279372 crossrefType "journal-article" @default.
- W2312279372 hasAuthorship W2312279372A5009213880 @default.
- W2312279372 hasAuthorship W2312279372A5030830562 @default.
- W2312279372 hasAuthorship W2312279372A5037177516 @default.
- W2312279372 hasAuthorship W2312279372A5037386752 @default.
- W2312279372 hasAuthorship W2312279372A5038023238 @default.
- W2312279372 hasAuthorship W2312279372A5044627353 @default.
- W2312279372 hasAuthorship W2312279372A5059435575 @default.
- W2312279372 hasAuthorship W2312279372A5074081568 @default.
- W2312279372 hasAuthorship W2312279372A5076696600 @default.
- W2312279372 hasAuthorship W2312279372A5076795570 @default.
- W2312279372 hasAuthorship W2312279372A5080337749 @default.
- W2312279372 hasAuthorship W2312279372A5087213651 @default.
- W2312279372 hasAuthorship W2312279372A5089890051 @default.
- W2312279372 hasAuthorship W2312279372A5089961811 @default.
- W2312279372 hasAuthorship W2312279372A5090674996 @default.
- W2312279372 hasBestOaLocation W23122793721 @default.
- W2312279372 hasConcept C112392421 @default.
- W2312279372 hasConcept C126322002 @default.
- W2312279372 hasConcept C142724271 @default.
- W2312279372 hasConcept C170493617 @default.
- W2312279372 hasConcept C171958077 @default.
- W2312279372 hasConcept C203014093 @default.
- W2312279372 hasConcept C204232928 @default.
- W2312279372 hasConcept C2775934546 @default.
- W2312279372 hasConcept C2776233030 @default.
- W2312279372 hasConcept C2777575956 @default.
- W2312279372 hasConcept C2777624698 @default.
- W2312279372 hasConcept C2778886723 @default.
- W2312279372 hasConcept C2778923194 @default.
- W2312279372 hasConcept C2780439664 @default.
- W2312279372 hasConcept C2780564577 @default.
- W2312279372 hasConcept C3019965523 @default.
- W2312279372 hasConcept C55493867 @default.
- W2312279372 hasConcept C62478195 @default.
- W2312279372 hasConcept C71924100 @default.
- W2312279372 hasConcept C86803240 @default.
- W2312279372 hasConcept C90924648 @default.
- W2312279372 hasConceptScore W2312279372C112392421 @default.
- W2312279372 hasConceptScore W2312279372C126322002 @default.
- W2312279372 hasConceptScore W2312279372C142724271 @default.
- W2312279372 hasConceptScore W2312279372C170493617 @default.
- W2312279372 hasConceptScore W2312279372C171958077 @default.